1,000% and still moving 🚀

This “comeback kid” is on fire

Issuer-Sponsored Content from Relmada Therapeutics, Inc*

Markets have been choppy lately, so I’ve been digging into an incredible comeback story. This biotech looked dead after a failed trial, then quietly rebuilt with new assets, insider buying, and fresh data. It’s now up nearly 1,000% over the last 52 weeks. Here’s the story.

TODAY’S TOP ALERT! 

Relmada Therapeutics (Nasdaq: RLMD)

👉RLMD is TODAY’S #1 ALERT*👈

Good afternoon, Folks,

Stocks are finally making a move up today after a week and a half of lackluster sessions.

The tech-heavy Nasdaq in particular is making a solid move higher, which is welcome news for Mag 7 holders. As of yesterday, all seven titans were down in 2026.

But amid this burst of optimism, my “tactical trade” idea for today is a standout play. Here’s where Relmada Therapeutics Inc (RLMD) is at as of this writing:

If you’ve been following since my pre-market alert, you’ve seen the stock hit over 15% – in just a few hours!

As I wrote to you this morning, the stock has made a huge comeback over the past year. It had already roared nearly 1,000% and after today’s move we’re looking at about 1,150%.

RLMD stands out among clinical-stage biotechs. I would know… I study these guys all the time…

The biggest concern investors usually have is with potential dilution. But on November 5, the company completed a $100 million underwritten offering “to support planned operations into 2028.” 

On top of that, company insiders have been buying up shares left and right, including when the stock was at its current price back in December:

Nobody is in a better position to know how a clinical program is advancing than company insiders, and here you have them putting real skin in the game. You love to see it.

There’s still plenty of trading day left, so stay tuned to RLMD to see if it powers through the close!

To Your Success,

*ISSUER-SPONSORED DISCLAIMER: This entity is owned by Sherwood Ventures LLC (SV). To more fully understand any SV subscription, website, application or other service, please review our full disclaimer located at https://bullseyealerts.com/disclaimer/

Just so you know, what you're reading is curated content for which we have received a monetary fee (detailed below) to create and distribute. Let's be clear that investing can be quite the roller coaster as stock prices can have wild swings up and down, so consider those crucial risks before you ever consider trading anything we discuss. Make sure you check out our full disclosure down below for the details on how we were paid, the risks, and why these results aren't what you'd call “typical.”

Just a quick heads up about this ad you're reading—as we’ve said, even though we like the company referenced above, and all the facts we discussed above are true to the best of our knowledge, we are running a business here. To distribute this information and help offset the costs of maintaining our large digital audience, in advance of writing the content above, we received thirty five thousand dollars (cash) from Relmada Therapeutics, Inc (via Sica Media) for a one day marketing program starting on February 18, 2026.

It might seem obvious, but while our client claims not to own any shares in Relmada Therapeutics, Inc, whoever ultimately paid them most likely owns shares. You should assume they are looking to sell some or all of them at any time after we send out this information, which might negatively affect the stock price. We may also buy or sell shares in the company at some point in the future, although neither Sherwood Ventures nor its owners own any shares of the company at this time. Also, keep in mind that due to the sheer size of our audience, if even a small percentage of people decide they want to buy this stock, it could potentially boost interest enough to hike up those share prices and cause a temporary spike, and the opposite is possible as the marketing campaign ends, though that is not always the case.

Now, diving right into Relmada Therapeutics, Inc might sound exciting. But remember, it’s like venturing into the wilderness—be aware that there's exceptional risk involved in trading. This isn't small potatoes we're talking about; you could lose every dime you put in, so always carefully think about what you’re doing. That’s why they call this trading, after all. We're shining a light on the good stuff about the company here, but it's on you to do your homework, make your own calls, and determine a plan for your own trading, hopefully with the help of your professional 1nvestment advis0r.

Oh, that brings us to another crucial point—we're not here to tell you (or even recommend) what you should do with your hard-earned money. We’re simply sharing our non-expert thoughts by highlighting some companies who are paying us and we like that could use some help telling their story to more people. We’re obviously biased in our writing. We’re not here to dig into anything that may be negative about the company; this is advertising, after all! Also, keep in mind that if we make some predictions about the future, these are technically known as “forward-L00king statements” under the securities acts, so take those with a grain of salt. As with all forecasts, they’re not set in stone, often wrong, and we certainly can’t know where the Company’s earnings, business, or share price will be tomorrow or a year from now.

Everything you read from us is all for your education, information, and possible entertainment. While we believe the info is reliable and accurate, we can't wear a cape and guarantee it. Before you jump into anything, make sure to talk it over with a pro—someone you trust who's licensed to give you real advice. To be clear, neither Sherwood Ventures nor its owners, employees, or independent contractors are registered as a securities broker-dealer, broker, 1nvest.ment advis0r (IA), or IA rep’s with the SEC, any state securities regulatory authority, or any self-regu1atory organization.

So, that's the scoop! If you're intrigued and want to learn more about the companies we talk about, hit up the SEC's website to dig into their filings and see the full picture.